News Hub | News Direct

Creo Medical Group FY22 results and recent funding - Proactive Research Analyst

Creo Medical Group PLC

Proactive Research Analyst John Savin gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO). Savin talks about the company's recent performance and key products, before moving on to look at how it is positioned for the future. He also touches on a recent placing that generated a net £32 million. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

ImmuPharma "looking forward" to upcoming FDA meetings

ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio, following what he calls a "very busy time" for the specialty biopharmaceutical company. He discusses the latest developments and next steps for the P140 platform, highlighting the importance of two upcoming meetings with the US FDA. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 28, 2023 03:00 AM Eastern Daylight Time

Video

Maureen McBride Named CEO of UNOS

United Network for Organ Sharing

Maureen McBride, Ph.D., has been named CEO of United Network for Organ Sharing (UNOS), the mission-driven, non-profit organization that serves as the nation’s organ donation and transplant system — the Organ Procurement and Transplantation Network (OPTN) — under contract with the federal government. “We conducted an exhaustive nationwide search for a new CEO and were pleased to find that the most qualified candidate is Dr. McBride,” said UNOS Board President Jerry McCauley, M.D., who chaired the Search Committee. “She impressed the Committee with her innovative spirit, clear-eyed vision of transformational change at UNOS and knowledge of the challenges facing the organ donation and transplantation community today. Since taking over as Interim CEO seven months ago, Dr. McBride has shown that she embodies a much-needed change in approach and operations at UNOS. She has put the organization on a new trajectory by increasing transparency and communication with the organ donation and transplantation community, regulators, Congress and the public, and advancing new initiatives to modernize and improve the organ donation and transplant system to benefit patients and ensure public trust.” Under McBride’s leadership, UNOS released an Action Agenda earlier this year, a comprehensive set of improvements in critical areas of the transplant system, including transparency, accountability, equity, transportation and modernization. McBride has worked for UNOS since 1995. She has served as Interim CEO since October 2022 and before that, as Chief Operating Officer managing the OPTN contract. She was also the organization’s Director of Research from 2006 to 2014 and contributed to more than 50 research manuscripts and publications. As CEO, she directs the efforts of 450 UNOS staff to ensure that the nation’s organ donation and transplant network efficiently and fairly serves the needs of transplant candidates and recipients, living donors and donor family members, and professionals in the field. She will be the first woman to lead the organization. “I am humbled, thrilled and energized to be selected to serve as CEO of UNOS,” McBride said. “As long as there are patients in desperate need of organs, we have more work ahead of us. As we move forward in our mission to save more lives, I look forward to leading UNOS during a time of immense change. As I said in my first official remarks as Interim CEO: we can do better, we must do better, and we will do better. We are excited to show our ongoing commitment to saving lives, how we are best situated to help usher in proposed improvements and how our expertise should remain an integral part of the system. Additionally, I am excited to continue working with UNOS’ other non-OPTN business lines to enhance and grow our organization.” In selecting McBride, the UNOS Corporate Affairs Committee agreed this is a pivotal moment in the organization’s history. They cited her leadership skills and proven ability to navigate organizational change both internally and externally as the lifesaving work continues and as UNOS prepares to respond to the federal government’s upcoming RFPs for the new OPTN contract. This includes her institutional knowledge of UNOS and the entire organ donation and transplant community; her experience in the field; her commitment to clear and frequent communication to build trust, understanding and consensus; and her unquestioned commitment to the organization and its mission to save as many lives as possible through organ donation and transplantation. She received her bachelor of science in mathematics from Loyola College in Maryland and her Ph.D. in biostatistics from Virginia Commonwealth University, Medical College of Virginia. McBride has served as the Executive Director of the OPTN since October 2022. She will begin her new role with UNOS immediately. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

April 27, 2023 02:36 PM Eastern Daylight Time

Image

News Release

NuGen Medical Devices begins feasibility study in the Netherlands for InsuJet and Ozempic

NuGen Medical Devices

NuGen Medical Devices executive chairman Tony Di Benedetto joined Steve Darling from Proactive to provide details about the company that is developing the next generation of needle-free technologies for both humans and animals. Di Benedetto shares with Proactive more about the technology behind products InsuJet and PetJet and also about an assessment and feasibility study in the Netherlands of InsuJet for Semaglutide or its more widely known name Ozempic. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 27, 2023 01:36 PM Eastern Daylight Time

Video

USDA’s ‘Defend the Flock’ Campaign Addresses How to Help Keep Your Backyard Chickens Safe from Bird Flu

YourUpdateTV

Over the last several years, more people have turned to raising chickens at home. But a highly infectious bird flu called Highly Pathogenic Avian Influenza (HPAI) has created challenges for backyard growers, already affecting more than 58 million birds nationwide. Recently, Dr. Julie Gauthier, the Assistant Director of Poultry Health at the U.S. Department of Agriculture, participated in a nationwide satellite media tour to discuss the crisis and how their ‘Defend the Flock’ campaign is helping address the issue. A video accompanying this announcement is available at: https://youtu.be/-7Wg4IcF5Bc The U.S. poultry industry is one of the largest in the world and an important sector of our agricultural economy. Disease outbreaks can devastate flocks, impact trade, cause job and financial losses, and affect prices on eggs, prepared poultry, and other staples. The Defend the Flock education program offers free tools and resources to help everyone who handles or works with poultry follow proper biosecurity practices. These practices will help keep your birds healthy and reduce the risk of avian influenza and other infectious diseases. Tips include: · Keep flocks away from open water and wild birds that can carry disease · Separating your poultry from the rest of your property, using only one entry and exit point · Clean regularly and wear dedicated clothes and shoes when tending to your flock · Clean equipment and vehicles with soap and water before and after they are near your flock · Don’t share tools, poultry supplies or equipment with other flock owners · Report sick birds and know the warning signs, including lower egg production, soft-shelled or misshapen eggs, and runny nose, sneezing and trouble breathing. Report any signs of illness or unexplained deaths to your veterinarian, animal health official, or call the USDA at 866-536-7593 For more tips and advice to keep your chickens safe, search online for ‘Defend the Flock’ About Dr. Julie Gauthier Dr. Julie Gauthier is Assistant Director for Poultry Health and a Veterinary Medical Officer at the U.S. Department of Agriculture/APHIS. The doctor is a Veterinary Medicine Prevention Officer for the U.S. Army Reserve where she has served for more than five years. Dr. Gauthier received her Master’s in Public Health from the Yale School of Public Health and her Doctorate in Veterinary Medicine from Michigan State University. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

April 27, 2023 10:31 AM Eastern Daylight Time

Video

RemSleep Holdings Inc. Provides Shareholder Update

RemSleep Holdings, Inc.

RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask as well as positive developments for its next generation masks which have shown internal indications of relief from those suffering with certain comorbidities in conjunction with their sleep apnea. The company previously announced DeltaWave testing was targeted to be completed in 14-18 weeks prior to submission for 510K clearance. The original timeline put the target towards mid to end of March of this year. After further review and discussion with the company’s partnering lab and our compliance director, the timeline has been extended 7-8 weeks. One of the lengthier tests in the protocol (Cytotoxicity) had been restarted roughly halfway through the testing process due to a contaminated sample. The source of contamination could not be identified but it was determined to not come from the mask itself. Out of caution for any impact on the final results, the test was halted, and a new test started with a sealed DeltaWave sample from the original sample batch provided to the testing lab. The current test is on track to be completed towards the middle to end of May as previously announced on the company Twitter feed. It is important to note that there was no product failure in the test; rather, it was procedurally driven due to an observation of contamination once the test had already begun. While these issues cannot be foreseen and every step is taken to prevent them, it is also standard practice to provide additional, sealed samples for testing in an event such as this. While the delay was unexpected and frustrating, preparing for the possibility ahead of time resulted in the delay being relatively minimal. The company recently announced a new test is being run in addition to those in the original protocol. The additional test was deemed prudent due to the ongoing recalls and scrutiny in the CPAP industry and to alleviate any potential concerns going forward based on these ongoing changes. However, due to the lengthier Cytotoxicity test being restarted, the additional test will have no impact on the May timeframe. To date, all completed tests have provided the results as expected and the company remains confident the remaining tests will show similar results. Once these tests have ended, the company expects it will take 3-6 weeks for Risk Management Assessments to be completed, 3rd party certification of toxicology results, and final compilation to submit to the FDA for 510K clearance. The company has just recently received positive news on their next generation DeltaWave masks with respect to design and performance. RemSleep believes this provides significant support to the design being unique for respiratory masks and ultimately what the company considers to be the pathway for relief for those aforementioned sufferers. The company continues to evaluate medical centers & sleep study centers to perform the tests & trials demonstrating that relief from a clinical standpoint. RemSleep believes the potential for these masks to compete in the institutional and residential spaces will position the company in a much better position strategically and financially over the DeltaWave alone. As the company previously discussed in the shareholder letter at the beginning of the year, CPAP device sales continue to be a focus. While RemSleep had several promising commitments early on that started the initiative and fell through, the last several months have shown several new sales channels opening up with orders being taken. While equipment sales are important for revenue and cash flow, ultimately the company is looking at sales of these devices to establish new sales channels and relationships to partner with once the DeltaWave line of masks are cleared. RemSleep CEO, Tom Wood, commented further: “Obviously the stopping and restarting of a critical test is frustrating as a CEO, shareholder, and a product designer. The regulatory landscape has changed dramatically since the last product I brought to market and the increased scrutiny of respiratory devices and masks in general certainly isn’t making it any easier. While frustrating, it also reaffirms the decision we made to hire Ms. Strzepek with her specific, regulatory experience with respiratory masks, to oversee the 510K process. She remains invaluable to navigating this fluid environment and addressing any issues ahead of time that could be cause for concern on the administrative and procedural processes. Despite these challenges, I have never been more confident or excited for the impact I believe RemSleep can have on the market with the DeltaWave as well as the next generation devices as we near the end of the testing process. It can be a difficult balance trying to share that confidence and excitement while dealing with the day-to-day issues, delays, and waiting but I hope that passion we must make these products successful continues to be seen and understood by our shareholders.” The company will continue to update investors as information becomes available and is confirmed. RemSleep appreciates the ongoing questions and interest in the DeltaWave products and will follow up accordingly in press releases, on the company website: www.remsleep.com, and through the company Twitter feed: @RemsleepInc About RemSleep Holdings Inc. RemSleep Holdings Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of Sleep Apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the RemSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make a difference and improve the condition of those suffering from Sleep Apnea. www.remsleep.com https://twitter.com/RemsleepInc Forward-Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company's future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Investor Relations Contact: Preya Narain info@preya.co Contact Details Preya Narain, Investor Relations info@preya.co Company Website https://remsleep.com/

April 26, 2023 11:44 AM Eastern Daylight Time

Software Effective Solutions "MEDCANA" (OTC: SFWJ) Provides Corporate Update for Shareholders

Software Effective Solutions Corp.

Software Effective Solutions, (OTC: SFWJ) (“The Company”, “SFWJ”) doing business as MedCana, is thrilled to provide a corporate update on its recent progress, expansion plans, and partnership opportunities. Major highlights With a positive outlook for Q2, Eko2O S.A.S. has increased sales potential into Central and South America as it looks into greenhouse and irrigation system opportunities in Panama and Uruguay. Production firms owned by MedCana are moving forward according to schedule and haven't run into any problems during the current development and construction phases. Talks between MedCana and the Mendoza administration in Argentina are going very well and are intended to examine potential subsidies for beginning operations there. Sales Opportunities in Central and South America are expanded by Eko2O S.A.S. Eko2O SA, a MedCana subsidiary, has successfully increased its sales potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook for Q2 has resulted from the company's expansion as it investigates new potential for greenhouse and irrigation system installations in Panama and Uruguay. These possibilities are anticipated to accelerate Eko2O's development and strengthen its position as a top supplier of innovative agricultural solutions in the cannabis sector. Smooth Progress by MedCana-Owned Production Companies The five production firms owned by MedCana are being built and developed in Medellín, Colombia, according to schedule and without any major setbacks. These businesses' ongoing entire crop cycle testing is providing insightful data on crop behavior monitoring, staff training, and production process improvement. To ensure the consistent delivery of high-quality cannabis products to clients and customers, MedCana is still committed to ensuring the seamless integration of manufacturing processes throughout its subsidiaries. MedCana Engages in Partnership Talks with Mendoza, Argentina Government MedCana has started talking with the Mendoza government in Argentina about possible incentives for starting operations there as part of its ongoing worldwide development strategy. These discussions are going quite well, and both parties are excited about the potential alliance. Support from the Argentinean government and the start of new operations there would greatly increase MedCana's market share in Latin America and solidify the company's position as the market leader in the world of cannabis. MedCana CEO Gabriel Diaz expressed his optimism, saying: "We are extremely pleased with the progress we've made in recent months, and the prospects for continued growth in the near future. Our expansion into Central and South America, the steady progress of our production companies, and our ongoing discussions with the Argentine government all point to a bright future for MedCana and its shareholders." ABOUT SFWJ: Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. Currently, MedCana has five companies focused on pharmaceutical cannabis production, one software company focused on managing processes for plant-to-patient operations. The recent acquisition an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of companies. MedCana's initial focus is on developing clients and companies in Latin America with an initial focus in Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Contact: Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co Contact Details MedCana info@medcana.co Company Website https://www.medcana.net/

April 26, 2023 09:00 AM Eastern Daylight Time

News Release

Consumer Automotive Finance, Inc. Acquires H2O and Solar Energy Solutions

Consumer Automotive Finance, Inc.

Consumer Automotive Finance, Inc. (OTC: CAFI) is a company that operates in the sports supplement, fitness equipment, and health and wellness industries. As part of its expansion strategy, the company seeks to acquire revenue-generating companies that complement its portfolio and enhance its position in these sectors. As part of its ongoing expansion strategy, Consumer Automotive Finance, Inc. is pleased to announce it acquired H2O and Solar Energy Solutions from Branded Legacy, Inc. (OTC: BLEG) for Twenty Million (20,000,000) restricted common stock. This acquisition perfectly complements its existing portfolio and reinforces its position in the market. This strategic move enables CAFI to offer sustainable solutions that prioritize consumer health and wellbeing while reducing their environmental impact. With hydration being a key factor in performance and overall health, having access to purified water is crucial. This new acquisition will provide consumers with high-quality, purified water that meets their needs, supporting their fitness and wellness goals. H2O and Solar Energy Solutions is a provider of water purification and solar energy systems based in central Florida. H2O and Solar Energy Solutions is a provider of water purification and solar energy systems based in central Florida, with over $430,000 in revenue generated in 2022. H2O and Solar Energy Solutions provide customized solutions for residential and commercial customers, offering free quotations and home testing to ensure customer satisfaction. With a strong focus on expanding its sales team, H2O and Solar Energy Solutions aims to generate over One Million Dollars ($1,000,000) in revenue in 2023. Consumer Automotive Finance, Inc. is confident that this acquisition will help H2O and Solar Energy Solutions obtain the necessary funding to achieve its projected growth. The company believes that the acquisition aligns with its own mission to offer innovative and dependable solutions to its customers, while also broadening its offerings and delivering even greater value to customers. "We are thrilled to announce the acquisition of H2O and Solar Energy Solutions," said Brandon Spikes, CEO of Consumer Automotive Finance, Inc. "As a company that values innovation and customer satisfaction, we believe that H2O and Solar Energy Solutions is an excellent fit for us. This acquisition will enable us to expand our product offerings and provide our customers with even more value." Previously announced the company has also enlisted legal counsel to effectuate a name and ticker symbol change that aligns with its evolving business objectives. About Consumer Automotive Finance, Inc.: Innate Global, Inc. (formerly Consumer Automotive Finance, Inc.) is a company with three subsidiaries that operate in the sports supplement, fitness equipment, and health and wellness industries, respectively. Its subsidiaries are 51, LLC, a sports supplement brand, The Quickness, which holds a patent for innovative sports training equipment designed to improve linebacker training, and Astound NMN, a brand of anti-aging DNA repairing supplements. The company is dedicated to providing innovative products and cutting-edge technology that help people achieve their fitness and wellness goals. Additionally, Innate Global, Inc. is actively seeking to acquire revenue-generating companies to further expand its portfolio. Safe Harbor Statement: The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. Contact: Consumer Automotive Finance, Inc. spikes41@gmail.com Contact Details Consumer Automotive Finance, Inc. spikes41@gmail.com

April 25, 2023 10:59 AM Eastern Daylight Time

News Release

Breast Surgical Oncologist discusses game-changing technology in Perimeter S-Series OCT system

Perimeter Medical Imaging AI

Natalie Stoberman is joined by Dr Amelia Tower, a Texas-based breast surgical oncologist and collaborator with Perimeter Medical Imaging AI, to discuss her recently published white paper based on case studies with Perimeter's S-Series OCT technology in breast cancer operations titled "Use of adjunct wide-field optical coherence tomography to visualize margins during breast conserving surgery for ductal carcinoma in situ: a case series" (read here https://perimetermed.com/wp-content/uploads/2023/03/SC-012_Case-Study-Breast-Oncology_Rev-A.pdf ). Tower says the technology allows surgeons to examine tissue in real-time during a lumpectomy, ensuring healthy margins of tissue and reducing the need for additional surgeries. She adds that the technology can also improve overall cosmetic results and reduce emotional and financial burdens on patients. She adds that she is hopeful that optical coherence tomography will become a standard of care for patients undergoing breast conservation therapy, and she advocates for further studies to explore the potential benefits of this technology. DISCLAIMER: The opinions expressed within the content are solely the author's and do not reflect the opinions and beliefs of the website or its affiliates. The S-Series Optical Coherence Tomography (OCT) System is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 25, 2023 10:55 AM Eastern Daylight Time

Video

Healthcare

Creo Medical Group FY22 results and recent funding - Proactive Research Analyst

ImmuPharma "looking forward" to upcoming FDA meetings

Maureen McBride Named CEO of UNOS

NuGen Medical Devices begins feasibility study in the Netherlands for InsuJet and Ozempic

USDA’s ‘Defend the Flock’ Campaign Addresses How to Help Keep Your Backyard Chickens Safe from Bird Flu

RemSleep Holdings Inc. Provides Shareholder Update

Software Effective Solutions "MEDCANA" (OTC: SFWJ) Provides Corporate Update for Shareholders

Consumer Automotive Finance, Inc. Acquires H2O and Solar Energy Solutions

Breast Surgical Oncologist discusses game-changing technology in Perimeter S-Series OCT system